Experts discuss the importance of successful adoption of biosimilars in the US health care system

Since 2015, Kaiser Permanente has saved over $200 million throughout its health systems by adopting biosimilar medicines. Kaiser Permanente, a community-based, not-for-profit, integrated delivery system serving 12.4 million members started by implementing Zarxio® (filgrastim-sndz). Made by global health care company Sandoz, it was the first biosimilar approved in the U.S. The path toward acceptance of this medicine was rigorous. A biosimilar is designed to match and have no clinically meaningful…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news